1. Home
  2. DLX vs PHAR Comparison

DLX vs PHAR Comparison

Compare DLX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deluxe Corporation

DLX

Deluxe Corporation

HOLD

Current Price

$27.77

Market Cap

1.2B

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.36

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLX
PHAR
Founded
1915
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
DLX
PHAR
Price
$27.77
$16.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$23.00
$38.00
AVG Volume (30 Days)
529.9K
31.0K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
4.21%
N/A
EPS Growth
52.54
N/A
EPS
1.80
N/A
Revenue
$2,133,200,000.00
N/A
Revenue This Year
$1.40
$27.75
Revenue Next Year
$1.66
$9.39
P/E Ratio
$15.83
$3,041.22
Revenue Growth
0.54
N/A
52 Week Low
$13.61
$7.50
52 Week High
$28.60
$21.34

Technical Indicators

Market Signals
Indicator
DLX
PHAR
Relative Strength Index (RSI) 59.76 44.14
Support Level $18.25 $16.35
Resistance Level $28.60 $17.65
Average True Range (ATR) 0.88 0.57
MACD -0.04 0.04
Stochastic Oscillator 75.77 50.44

Price Performance

Historical Comparison
DLX
PHAR

About DLX Deluxe Corporation

Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: